Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Bioorg Med Chem Lett. 2013 Feb 15;23(4):975-8. doi: 10.1016/j.bmcl.2012.12.048. Epub 2012 Dec 27.
A major liability of existing nicotine vaccine candidates is the wide variation in anti-nicotine immune responses among clinical trial participants. In order to address this liability, significant emphasis has been directed at evaluating adjuvants and delivery systems that confer more robust potentiation of the anti-nicotine immune response. Toward that end, we have initiated work that seeks to exploit the adjuvant effect of liposomes, with or without Toll-like receptor agonist(s). The results of the murine immunization study described herein support the hypothesis that a liposomal nicotine vaccine formulation may provide a means for addressing the immunogenicity challenge.
现有尼古丁疫苗候选物的一个主要缺陷是临床试验参与者的抗尼古丁免疫反应差异很大。为了解决这个问题，人们非常重视评估佐剂和输送系统，以更有效地增强抗尼古丁免疫反应。为此，我们已经开始研究利用脂质体的佐剂作用，无论是否有 Toll 样受体激动剂。本文所述的小鼠免疫研究结果支持这样一种假设，即脂质体尼古丁疫苗制剂可能为解决免疫原性挑战提供一种手段。
